InnoCare Pharma Ltd. (HKG:9969) unit InnoCare Pharma Inc. dosed the first subject in a phase 1 trial of ICP-054 in China.
Preclinical data shows the potential of ICP-054 to be a differentiated oral therapy for autoimmune and inflammatory diseases associated with dysregulated IL-17 signaling, according to a Wednesday Hong Kong bourse filing.
The Hong Kong-listed drugmaker is developing the drug in partnership with Zenas BioPharma.
Refex Industries (NSE:REFEX, BOM:532884) received an order worth 365 million Indian rupees from a Navratna public sector steel company for supply of bulk industrial commodity, according to a Wednesday filing.The order is to be executed within 40 days, the filing said.
Zaggle Prepaid Ocean Services (NSE:ZAGGLE, BOM:543985) appointed Venkatesh Ramachandran as group chief financial officer, effective May 18, according to a Wednesday filing on Indian bourses.Following the appointment, Rajesh Tummalaganti will cease to be interim CFO, effective May 17, the company said. He will continue as deputy chief financial officer, it added.
Smruthi Organics' (BOM:540686) net profit more than halved to 10.7 million Indian rupees in the fiscal fourth quarter from 22.3 million rupees a year earlier, according to an Indian bourse filing on Wednesday.Earnings per share for the quarter ended March 31 contracted to 0.93 rupees from 1.95 rupees a year ago.The pharmaceutical company's revenue slipped year-on-year to 290.9 million rupees from 380.9 million rupees, the filing said.The company's board recommended a dividend of 1.5 rupees per share for fiscal 2026 ended March 31.Shares of the company were up 4% in after-market hours.